Takeda logo

Takeda Oncology Pipeline: Investigational Therapies for Cancer Treatment | Takeda Oncology

Our Pipeline

Our Pipeline

We are advancing a pipeline of investigational therapies with the highest potential to reach patients. We are currently focused on four core modalities: antibody drug conjugates (ADCs), bispecifics, small molecules and gamma delta T cell therapies. We are evaluating investigational therapies that leverage these modalities in solid tumors - with a focus on thoracic and gastrointestinal cancers - and hematologic cancers.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational therapyModalityInvestigational indicationPhase
Plus

Brentuximab vedotin*

ADC

Newly diagnosed Hodgkin lymphoma (EU)

Phase 3

Plus

Cabozantinib*

Small molecule

Metastatic castration-​resistant prostate cancer (JP)

Phase 3

Plus

Fruquintinib*

Small molecule

Previously treated metastatic colorectal cancer (JP)

Filed

Plus

Dazostinag (TAK-676)

Small molecule

Solid tumors

Phase 1/2

Plus

Mirvetuximab soravtansine-gynx (TAK-853)

ADC

Folate receptor alpha (FRα)-positive ovarian cancer (JP)

Phase 1/2

Plus

TAK-012

Gamma delta T cell therapy

Acute myeloid leukemia

Phase 1/2a

Plus

TAK-186

Bispecific

Solid tumors

Phase 1/2

Plus

TAK-280

Bispecific

Solid tumors

Phase 1/2

Plus

TAK-500

ADC

Solid tumors

Phase 1/2

  • *Marketed products have received approval in one or more jurisdictions.

  • All programs have global development rights unless otherwise noted.

  • GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Investors

To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore IR
Banner Image

Explore More

Card image

Science

Decades of leadership in Oncology with a diverse and robust pipeline.
Card image

Partnership Strategy

We believe the best way to achieve our aspiration to cure cancer is by working together.
Newsroom

Newsroom

Keep up on the latest Oncology news by visiting our newsroom.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23